Skip to content

EBIT at other companies

Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$169M-18.2%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
-$110.03M-3.2%
ALN
Alnylam PharmaceuticalsALNY
$268.64M+1,386%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Arrowhead Research logo
Arrowhead ResearchARWR

Other financials

Income statement

See full
Revenue$156.4M+7.5%
Gross profit$151.0M+7.1%
Operating income-$701.6M-3,405%
Net income-$721.8M-2,255,763%
EPS (diluted)-$2.98

Balance sheet

See full
Cash & equivalents$173.4M+62.2%
Total debt$411.8M+24.7%
Total equity-$553.8M-22.6%
Total assets$465.1M-3.1%

Cash flow

See full
Operating cash flow-$61.8M-125%
CapEx$403.0K+182%
Free cash flow-$62.2M-125%

Valuation

See full
Market cap$2.37B+52.3%
Enterprise value$2.6B+46.7%
P/S2.7×-0.4×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-43.1%-49.7pp
Net margin-51.7%-69.7pp
FCF margin35%

Returns & leverage

See full
Return on equity-882.8%
Debt / equity0.1×
Current ratio1.9×-1.0×

Where this comes from

Calculated from BioCryst Pharmaceuticals’s reported figures.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioCryst Pharmaceuticals's EBIT?
BioCryst Pharmaceuticals (BCRX) reported EBIT of -$701.6M in Q1 2026.
How has BioCryst Pharmaceuticals's EBIT changed year-over-year?
BioCryst Pharmaceuticals's EBIT decreased by 3405.2% year-over-year, from $21.23M to -$701.6M.
What is the long-term trend for BioCryst Pharmaceuticals's EBIT?
Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's EBIT has grown at a 17.7% compound annual growth rate (CAGR), from -$177.72M to $340.99M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.